



INVESTOR PRESENTATION

TSX-V:
CANB.V

SPRING 2021

A preliminary prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in each of/certain of the provinces of Canada, other than Quebec. A copy of the preliminary prospectus, and any amendment, is required to be delivered with this document. The preliminary prospectus is still subject to completion. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued. This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the preliminary prospectus, the final prospectus and any amendment for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.

A copy of the preliminary short form prospectus (the “Prospectus”) has been filed with the securities regulatory authorities in each of the provinces of Canada, except Québec, but has not yet become final for the purpose of the sale of securities. Information contained in the Prospectus may not be complete and may have to be amended. The securities may not be sold until a receipt for the Prospectus is obtained from the securities regulatory authorities. No securities regulatory authority has expressed an opinion about the securities described in the Prospectus and it is an offence to claim otherwise. The Prospectus constitutes a public offering of the securities only in those jurisdictions where they may be lawfully offered for sale and therein only by persons permitted to sell such securities.

The securities and underlying securities offered under the Prospectus have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States of America, its territories and possessions, any state of the United States or the District of Columbia (collectively, the “United States”) or “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act (“U.S. Persons”)) unless exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws are available. This Prospectus does not constitute an offer to sell or a solicitation of an offer to buy any of the securities offered hereby in the United States or to, or for the account or benefit of, persons in the United States or U.S. Persons. See “Plan of Distribution”. Information has been incorporated by reference in the Prospectus from documents filed with securities commissions or similar authorities in Canada. Copies of the documents incorporated herein by reference may be obtained on request without charge from the Corporate Secretary of CanadaBis Capital Corp at 255C Clearview Drive, Red Deer, County, Alberta, Canada T4E 3B6 (1-888-784-4621 or 1-888-STIGMA1) and are also available electronically at www.sedar.com.



DISCLAIMER

This document contains forward-looking statements and forward-looking information regarding CanadaBis Capital Inc., its subsidiaries and affiliates (“CanadaBis” or the “Company”) including but not limited to such statements relating to:

- The expectations regarding legislation, regulations and licensing related to the cultivation, production and sale of cannabis products by the Company;
The expected number of users of medical cannabis or the size of the medical cannabis market in Canada and globally;
- The potential time frame for the introduction of legislation to legalize recreational cannabis use in Canada and globally and the potential form that this legislation will take;
- The potential size of the recreational cannabis market in Canada and globally;
- The Company’s expectations with respect to meeting major milestones and obtaining a license to produce and
- The Company’s expectations with respect to the volume of cannabis produced by month.
- The Company’s proposed monthly production demand.

The words “plans”, “expects”, “is expected”, “budget”, “projects”, “scheduled”, “estimates” “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or statements that certain actions, events, or results “may”, “could”, “would”, “might”, or “will” occur are all forward-looking statements. Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable at the date that such statements are made. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Forward-looking statements contained herein are made as of the date indicated on the title page. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements in this document. The Company does not undertake to update any forward-looking statements in this document except as required by applicable securities laws.



POSITIONING

TSX-V:
CANB.V

CanadaBis Capital is a publicly traded Canadian cannabis company with hydrocarbon concentrate (BHO) processing capabilities, uniquely equipped, experienced and licensed to pursue 3.0 product leadership within Canada via in-house brands and white-label partnerships.

Our unique positioning, combined with our retail pillar, allows us to remain engaged with those who drive industry trends to ensure we remain proactively relevant and recognized for high quality as we, and those we serve, continue to evolve.


MISSION

To establish ourselves as agile, approachable and available providers of 3.0 cannabis concentrates; recognized by provinces, retailers and consumers alike as a trusted ally and committed partner in the quest for category growth.

VISION

Canada's recognized leader in cannabis hydrocarbon concentrates positioned advantageously to operate with independent agility, grow organically and partner strategically.


POSITIONING cont



KEY POINTS:

- Concentrates are only just emerging in the Canadian market, and represent a small fraction of total sales, approximately 2%.
- Growth of market segment expected to reach levels comparable to more mature US markets, approximately 14%
- Represents ~7x growth in the near term
- The company has the ability to capture this market share as the costs and licensing process for new LPs to enter are daunting.
- Historical results reflect only sales in Alberta and Saskatchewan. Ontario and BC are currently onboarding our SKUs at approximately 25% of the volume they will need if trials are successful.
- 32 SKUs launched across Canada: AB, BC, ONT, MB, SASK, NB & NS
- While dry flower product margins continue to drop, concentrates margins remain high. Low-priced, reliable fresh frozen inputs and an all-in-house approach to controlling costs positions us to offer consistent, high-value, certified safe offerings at lower cost than most.

OUR BRANDS



Chapter 1 products represent our first suite of hydrocarbon (BHO) concentrates and acts as a brand platform from which to showcase our unique processing abilities via several first-to-markets. Our collection to-date has featured flavourful, aromatic and potent high-terpene, full-spectrum extract (HTFSE) concentrates including strain-specific shatters, badders, budders, caviar, RSO and more.

Thus far, everything we have produced has attracted the attention of our current third-party product partners. As such, our Chapter 1 products are typically released in limited batches, and are either fine-tuned, rebranded or removed from the province completely once we've attracted a high-volume, third-party product partner invested in competing for significant market share, willing to fill that space with their own branded offering through a third-party, high-volume, white-label partnership.



Dab Bods represents a brand positioned to (re)introduce concentrates to the public, acknowledging that the public traditionally takes its time warming up to anything new in the cannabis space.

By combining an approachable, education-focused brand with some of the lowest prices in-market, our sights are set on convincing both new-consumers and black-market loyalists to try something that we know will suit their needs.

Whether our customers are new to cannabis or well-versed, we believe our full-spectrum, BHO products can stand up to anything in the market today - but we have yet to see anyone match the prices we can offer thanks to our unique ability to keep cost control in-house.



This brand was designed to offer the very best in live-resin hydrocarbon cannabis concentrates and showcases recipes and product categories that few, if any, can achieve.

Currently, our live-resin, high-terpene, full-spectrum extract (HTFSE) vape cartridges offer a superior consumption experience filled with potent natural aromas and flavours, complex cannabinoid profiles a rich experience aided by the entourage effect; the synergistic activity of the cannabis' full-spectrum of compounds such as cannabinoids, terpenes and flavonoids.

By offering a true full-spectrum experience, at a low price point equal to some of the lower-priced distillates, we have attracted the attention and praise of provinces, retailers and end-consumers alike.



D
DABBODS
 SHATTER
 POWERFULLY UNASSUMING.



CANNABIS CONCENTRATES FROM A SOURCE YOU CAN TRUST.



D DABBODS
 SAYS
 "DIFFERENT STROKES FOR DIFFERENT FOLKS"



D DABBODS
 SAYS
 "WORTH THE GRILL"

D DABBODS
 SAYS
 "DON'T MESS WITH THE THERMOSTAT"

D DABBODS
 SATIVA STRAIN
 100% THC
 0% CBD

D DABBODS
 INDICA STRAIN
 100% THC
 0% CBD

D DABBODS
 BRO SHATTER
 SATIVA STRAIN
 22.4%
 TOTAL CANNABINOIDS
 708.1MG/G
 TOTAL THC
 708.1MG/G
 TOTAL CBD
 1.61MG/G

D DABBODS
 SATIVA STRAIN
 100% THC
 0% CBD

D DABBODS
 INDICA STRAIN
 100% THC
 0% CBD

A LITTLE OVERWEIGHT
 OUR STANDARD IS THE
 APPROX. WEIGHT OF THE
 CHICKEN LEG. WE GRILL IT
 AS CLOSE TO AS POSSIBLE.

UNASSUMINGLY STRONG
 WHILE OTHERS WORRY
 ABOUT POWER, WE FOCUS
 EXCLUSIVELY ON POWER.



D DABBODS
 SAYS
 "FIRST WE GRILL, THEN WE CHILL"

FINALLY... EXTRACTS FOR EVERY BODY.

D DABBODS

D DABBODS
 SAYS
 "DON'T MESS WITH THE THERMOSTAT"

GET COMFORTABLE WITH CONCENTRATES



NOW AVAILABLE ACROSS CANADA



D DABBODS
 SAYS
 "DON'T MESS WITH THE THERMOSTAT"



TALK TERPY TO ME
DEVILSHLY DANK

BLACK NGL

LIVE-RESIN FULL-SPECTRUM HTFSE/HCFSE BHO VAPE CARTS

BLACK NGL



WHITE NGL
LIVE RESIN CARTRIDGES

INDICA STRAIN
TOP TERPENES
FLAVOUR
TOTAL CANNABINOIDS
TOTAL TERPENES



WHITE NGL
LIVE RESIN CARTRIDGES

INDICA STRAIN
TOP TERPENES
FLAVOUR
TOTAL CANNABINOIDS
TOTAL TERPENES



WHITE NGL
LIVE RESIN CARTRIDGES

INDICA STRAIN
TOP TERPENES
FLAVOUR
TOTAL CANNABINOIDS
TOTAL TERPENES



WHITE NGL
LIVE RESIN CARTRIDGES

INDICA STRAIN
TOP TERPENES
FLAVOUR
TOTAL CANNABINOIDS
TOTAL TERPENES



WHITE NGL
LIVE RESIN CARTRIDGES

INDICA STRAIN
TOP TERPENES
FLAVOUR
TOTAL CANNABINOIDS
TOTAL TERPENES



WHITE NGL
BLACK NGL

THERE'S TWO SIDES TO EVERY STORY...
...and every cannabinoid.

WHICH SIDE OF THE SPECTRUM ARE YOU?

BLACK NGL

WHITE NGL



WHITE NGL
LIVE RESIN CARTRIDGES

INDICA STRAIN
TOP TERPENES
FLAVOUR
TOTAL CANNABINOIDS
TOTAL TERPENES



WHITE NGL
LIVE RESIN CARTRIDGES

INDICA STRAIN
TOP TERPENES
FLAVOUR
TOTAL CANNABINOIDS
TOTAL TERPENES

WE WOULDN'T CHANGE A THING

BLACK NGL
LIVE RESIN CARTRIDGES

SATIVA STRAIN
TOP TERPENES
FLAVOUR
TOTAL CANNABINOIDS
TOTAL TERPENES

BLACK NGL
TRACTS

SEXY. STRONG. STYLISH. SATIVA.

BLACK NGL

TEMPTATION COMES IN MANY FORMS
FULL SPECTRUM CONCENTRATES

WHITE NGL
BLACK NGL

OFFERING SO MUCH MORE THAN DISTILLATES

WHITE NGL


NOW AVAILABLE ACROSS CANADA

WHITE NGL
INTENSE, FULL-SPECTRUM, INDICAS

PRODUCTION NUMBERS



VOLUME OF CANNABIS GRAMS PRODUCED BY MONTH (INTERNAL AND THIRD-PARTY BRANDS)




JANUARY 2021*:
NATIONAL ORDER FREEZE

MARCH 2021**:
PROJECTED - TOTAL #TBD

APRIL 2021***:
SUNDIAL CONTRACT BEGINS



FIRST 100 LOTS OF CONCENTRATES PRODUCED BY TYPE



RECENT ACHIEVEMENTS

STIGMA
grow



- ✓ Successful initial launch of 5 SKUs for first-to-market BHO concentrate products in 2020; current product list has expanded to 32 SKUs.
- ✓ Currently operating within our wholly-owned cultivation facility.
- ✓ Nature of our products not susceptible to the same negative FV adjustments as dried flower
- ✓ Tried and true production methods ensure costs remain relatively stable despite significant increases in production volume.

- ✓ Two-Year White-Label Contract (Sundial) announced April 6, 2021.
- ✓ Current Average Monthly Production Demand (Not Including Ont):
Our Brands: 15,000 G/Month
Third-Party Min: 35,000 G/Month
Third-Party Max: 50,000 G/Month
- ✓ Proposed Monthly Production Demand Including Ontario (April – Forward):
Our Brands: 35,000+ G/Month

- ✓ Current extraction capacity of 800,000 one-gram units per month providing ample space for extraction processing expansion.
- ✓ Secured active sales contracts with seven provinces:
 - Alberta – Since Q4 2020
 - Nova Scotia – Since Q4 2020
 - Manitoba – Since Q4 2020
 - Saskatchewan – Since Q4 2020
 - British Columbia – Since Q1 2021
 - Ontario – Since Q1 2021
 - New Brunswick – Since Q1 2021

CAPITALIZATION AND SUMMARY FINANCIAL INFORMATION



Summary Quarterly Financial Information		31-Jul-20	31-Oct-20	31-Jan-21	30-Apr-21
Provincial Sales - Initial orders	AB/SK				BC/ON/MB/NB
Provincial Sales - Follow-on orders			AB/SK	AB/SK	AB/SK
Extraction and tolling	(C\$MM)	2.9	0.8	1.5	
Retail – Red Deer, Alberta	(C\$MM)	0.4	0.3	0.4	
Cultivation	(C\$MM)	0.3	0.1	0.0	
Total Revenue	(C\$MM)	\$3.6	\$1.2	\$1.8	
Cost of sales excl. FV adjustments	(C\$MM)	2.3	0.8	1.1	
Gross profit	(C\$MM)	\$1.3	\$0.4	\$0.7	
Overhead	(C\$MM)	1.0	0.8	0.8	
Cash based EBITDA	(C\$MM)	\$0.3	(\$0.4)	(\$0.1)	
FV adjustments	(C\$MM)	0.1	0.0	0.2	
Share based comp	(C\$MM)	0.1	0.2	0.1	
Accounting based EBITDA	(C\$MM)	\$0.1	(\$0.6)	(\$0.4)	

Hypothetical Economics to Break-Even EBITDA		
Gross Margin on New Contracts	(Range)	35%
	to	40%
Monthly New Revenue required for EBITDA-Breakeven	(C\$ 000s)	\$100
	to	\$120
<i>Required increase in revenue from current run-rate</i>	(Range)	17%
	to	20%


Price data as of April 1, 2021; financial statement and capitalization data as of January 31, 2021 including subsequent event disclosures in the financial statements. Totals may not equal due to rounding.

* Debt representative of a five-year mortgage on property valued at \$22M. Floating rate at Prime +1% is in good standing.

Capitalization Table		
Share Price	(C\$)	\$0.175
Basic Shares Outstanding	(MM)	136.0
Basic Market Capitalization	(C\$MM)	\$23.8
ITM Dilutives (Treasury Stock Method)	(MM)	0.2
Fully Diluted ITM Shares Outstanding	(MM)	136.2
Fully Diluted ITM Market Capitalization	(C\$MM)	\$23.8
OTM Dilutives	(MM)	12.6
OTM Dilutives Weighted Avg. Strike Price	(C\$)	\$0.31
OTM Dilutives Weighted Avg. Yrs Remaining	(#)	3.4
Debt*	(C\$MM)	\$5.6
Cash	(C\$MM)	\$0.1
Net Debt	(C\$MM)	\$5.4
Fully Diluted ITM Enterprise Value	(C\$MM)	\$29.3

Summary of Float		% of Shares O/S	
Basic Shares Outstanding	(MM)	136.0	100%
Less:			
Travis McIntyre (CEO)	(MM)	68.8	51%
Other Management and Directors	(MM)	6.2	5%
Institutions	(MM)	22.1	16%
		97.1	71%
Free Float	(MM)	38.9	29%

Liquidity		% of Float O/S	
Total Volume - 3 Months	(MM)	13.7	35%





CAUTIONARY STATEMENTS

Prospective investors should rely only on the information contained in the preliminary short form prospectus dated April [7], 2021 (the “Prospectus”). This presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information contained in the Prospectus and the information incorporated therein, including the Annual Information Form for the year ended July 31, 2020 for CanadaBis Capital Inc. (the “Corporation”). The Corporation and the Agents (as such term is defined in the Prospectus) are not offering to sell the Units (as such term is defined in the Prospectus) or any underlying securities of the Corporation in any jurisdiction where the offer or sale of such securities is not permitted. This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

This presentation includes market and industry data which was obtained from various publicly available sources and other sources believed by the Corporation to be true. Although the Corporation believes it to be reliable, the Corporation has not independently verified any of the data from third-party sources referred to in this presentation, or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Corporation does not make any representation as to the accuracy of such information.

FINANCIAL INFORMATION

Certain financial information included in this document is unaudited. There is a material risk that the audited financial results would differ significantly from unaudited financial information presented herein.

Certain information in this Presentation contain references to non-IFRS measures, such as EBITDA, that do not have standardized meaning under IFRS as prescribed by the International Accounting Standard Board and are therefore unlikely to be comparable to similar measures presented by other companies. These measures are provided as additional information to complement IFRS measures by providing further understanding of the Corporation’s operations from management’s perspective. Non-IFRS measures should not be considered in isolation or as a substitute for analysis of financial information under IFRS.

INVESTOR RELATIONS

invest@canadabis.com

1-888-STIGMA1